Abcam, ab120223, FK506 (Tacrolimus), Immunosuppressant

Size: 10mg / 50mg
MW 804 Da, Purity >98%. Immunosuppressant. Complexes with FKBP-12 to inhibit calcineurin. Achieve your results faster with highly validated, pure and trusted compounds.
Key facts
CAS number:104987-11-3,
Purity:>98%,
Form:SolidSee storage information,
Source:Streptomyces tsukubaensis,
Molecular weight:804 Da,
Molecular formula:C44H69NO12,
PubChem:445643,
Nature:Native,
Solubility:Soluble in DMSO to 100 mM,
Biochemical name:Tacrolimus,
Biological description:Immunosuppressant. Complexes with FKBP-12 to inhibit calcineurin.,
Canonical smiles:CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,
Isomeric smiles:C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,
InChi:InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1,
InChiKey:QJJXYPPXXYFBGM-LFZNUXCKSA-N,
IUPAC Name:(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone

Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Store under desiccating conditions, The product can be stored for up to 12 months

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FKBP12 also known as FKBP-12 or FKBP12 protein is a small protein with a molecular weight of approximately 12 kDa. It belongs to the family of immunophilins and acts as a peptidyl-prolyl cis-trans isomerase (PPIase) facilitating the folding of proteins by catalyzing the isomerization of proline residues in polypeptides. The FKBP12 protein is expressed in various tissues throughout the body including the brain heart and skeletal muscles. It plays a mechanical role in binding certain macrolide antibiotics such as FK506 (tacrolimus) influencing their biological effects by altering protein conformation.
Biological function summary
FKBP12 is significant in cellular mechanisms beyond protein folding. It interacts with and forms complexes with other proteins such as ryanodine receptors and transforming growth factor-beta (TGF-β) receptors impacting calcium signaling and cell growth. FKBP12's interaction with FK506 has been extensively studied because it forms a complex that inhibits calcineurin ultimately leading to immunosuppressive effects. This property of FKBP12 makes it important for modulating the immune response and has importance in transplant medicine.
Pathways
FKBP12 is actively involved in calcium signaling and TGF-β signaling pathways. FKBP12 influences these pathways by binding to ryanodine receptors affecting calcium release from intracellular stores and also modulating the function of TGF-β receptors impacting cellular growth and proliferation processes. It is associated with proteins such as calcineurin and Smad proteins in these pathways maintaining cellular homeostasis and regulating immune and inflammatory responses.
FKBP12 plays a role in immunological and proliferative diseases. It is implicated in autoimmune disorders due to its interaction with FK506 leading to the suppression of unwanted immune responses. FKBP12 is also linked to cardiac hypertrophy as its modulation of calcium release through ryanodine receptors can affect heart muscle function. The protein interacts with calcineurin in these contexts contributing to pathological processes in these diseases. Researchers target FKBP12 with ELISA and other assays to investigate its involvement in these disorders and assess therapeutic interventions.